Compare ACNB & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNB | QTTB |
|---|---|---|
| Founded | 1857 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.3M | 450.1M |
| IPO Year | 1994 | 2018 |
| Metric | ACNB | QTTB |
|---|---|---|
| Price | $64.45 | $10.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $58.00 | $13.00 |
| AVG Volume (30 Days) | 65.3K | ★ 540.3K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $191,821,000.00 | $53,737,000.00 |
| Revenue This Year | $13.18 | N/A |
| Revenue Next Year | $1.91 | N/A |
| P/E Ratio | $22.80 | ★ N/A |
| Revenue Growth | ★ 45.10 | N/A |
| 52 Week Low | $42.60 | $1.78 |
| 52 Week High | $67.60 | $23.57 |
| Indicator | ACNB | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 27.63 |
| Support Level | $62.78 | $4.59 |
| Resistance Level | $65.62 | $16.85 |
| Average True Range (ATR) | 1.65 | 0.70 |
| MACD | -0.20 | -0.23 |
| Stochastic Oscillator | 29.87 | 3.18 |
ACNB Corp is the financial holding company. Through its wholly-owned subsidiaries, it provides a full range of retail and commercial financial services in Pennsylvania and Maryland through its network of community banking offices. It also provides property, casualty, health, life and disability insurance serving personal and commercial clients through offices in Westminster, Maryland, and Gettysburg, Pennsylvania and is licensed to do business. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage; and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).